Good morning. I'm Tom DesRosier, Executive Vice President, Chief Legal Officer, and Secretary of Seres Therapeutics, and Chairperson of today's meeting. I'm very happy to welcome you to our reconvened 2026 Annual Meeting of Stockholders. From the company, we also have Richard Kender, Executive Chair and Interim Chief Executive Officer, and Kristen Grogan, our Vice President, Assistant General Counsel, who will serve as Secretary of this meeting. We also have on the line the following members of the Board of Directors: Dennis Ausiello, Stephen Berenson, Willard Dere, Claire Fraser, Kurt Graves, Rob Rosiello, and Eric Shaff. In addition, we have Holly Reeves of PricewaterhouseCoopers, the company's independent auditor, who is available to respond to appropriate questions via the question-and-answer function on the Annual Meeting webpage; a nd Anna Hagberg-Cit o, a representative of Broadridge Financial Solutions, who will serve as the Inspector of Election at today's meeting. I now call the meeting to order. We will proceed with the formal portion of the meeting as indicated in the notice of annual meeting and the company's proxy statement. The polls opened today, July 8th, 2026, at 8:00 A.M. Eastern Time for voting on all matters before the meeting. If you have not already voted and wish to vote, the polls will remain open until we finish presenting the proposals and close the polls. You do not need to vote during the meeting if you have already voted and do not wish to change your vote. On the virtual meeting webpage, you will find the agenda for the meeting. You will also find the rules of conduct for today's meeting. Please review these rules carefully. Note that only stockholders who are logged into the meeting using their 16-digit control number will be able to vote and submit questions at today's meeting. If you would like to submit a question, you may enter your question in the question- and- answer function on the Annual Meeting webpage. The Secretary of the meeting will file the proof of mailing of the meeting with the records of the meeting. All stockholders of record on April 13th, 2026, or holders of a valid proxy are entitled to vote at today's meeting. The Inspector of Election, Ms. Hagberg-Ci to, has signed the customary oath of office to execute her duties with strict impartiality. We will file this oath with the records of the meeting. There were 9,632,111 shares of common stock held of record on April 13, 2026. A majority of these shares are necessary for a quorum, and Ms. Hagberg-Ci to has informed me that more than a majority of the shares are represented at this meeting online or by proxy. I therefore declare that a quorum is present at this meeting to be duly constituted for the transaction of business. The stockholders will consider five proposals at today's meeting. The board recommends that the stockholders vote for proposals one through five. The first proposal is the election of Stephen Berenson, Claire Fraser, and Richard Kender to serve as Class II Directors of the company for a term expiring at the 2029 Annual Meeting of Stockholders. The second proposal is the ratification of the Audit Committee's appointment of PricewaterhouseCoopers as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The third proposal is the approval of the following resolution. Resolved, that the company's stockholders approve by a non-binding advisory vote the compensation of the named executive officers as disclosed in the company's proxy statement for the 2026 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the compensation tables and narrative discussion. The fourth proposal is the approval of an amendment and restatement of the Seres Therapeutics, Inc 2025 Incentive Award Plan to increase the number of shares available for issuance under the plan. The fifth proposal is the approval of an adjournment of the annual meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of this annual meeting to approve proposal four. If you wish to vote and you haven't already, please vote now by clicking on the voting button on the web portal and following the instructions. You do not need to vote electronically if you have already sent in your signed proxy or if you have voted by telephone or internet. We will pause for approximately 30 seconds before closing the voting polls. The time is now 8:05 A.M. on July 8th, 2026, and the polls are now closed for voting. The Inspector of Election will count the votes. Based on the preliminary report of the Inspector of Election, Stephen Berenson, Claire Fraser, and Richard Kender have been elected as Class II Directors. Congratulations. The appointment of PricewaterhouseCoopers as our independent auditor for 2026 has been ratified. The resolution to approve, on an advisory basis, the compensation of our named executive officers has been approved. The amendment and restatement of the Seres Therapeutics, Inc 2025 Incentive Award Plan to increase the number of shares available for issuance under the plan has been approved. The proposal to approve an adjournment of the meeting, if necessary, to solicit additional proxies, has been approved. However, as proposal four has passed, it is not necessary to adjourn the annual meeting. The final report of the Inspector of Election will be kept with the company's records of the annual meeting, and a final tally of the votes will be published within four business days in a current report on Form 8-K to be filed with the Securities and Exchange Commission. This formal portion of the meeting has now concluded. I want to thank you for participating and for your interest in Seres Therapeutics. We will now move to the final topic of the agenda, questions and answers. Please note that we will only be answering questions that are within the rules of conduct, and only stockholders who have logged into the meeting using their 16-digit control number are able to submit a question through the question area of the web portal. Ms. Grogan, are there any questions that have been submitted that comply with the rules of conduct? No, there are no questions. Please proceed with your closing remarks. Thank you, Kristen. In closing, I want to thank all of our stockholders and everyone on the line today for your interest in the affairs of Seres Therapeutics. This concludes our annual meeting. Ladies and gentlemen, thank you for your participation, and you may now disconnect.